PMID- 11356744
OWN - NLM
STAT- MEDLINE
DCOM- 20010726
LR  - 20190513
IS  - 0263-2136 (Print)
IS  - 0263-2136 (Linking)
VI  - 18
IP  - 3
DP  - 2001 Jun
TI  - Proton pump inhibitors: a study of GPs' prescribing.
PG  - 333-8
AB  - BACKGROUND: There has been a rapid increase in proton pump inhibitor (PPI) 
      prescribing in recent years, and controlling the cost and improving the quality 
      of prescribing is an issue of concern to many GPS: OBJECTIVE: Our aim was to 
      compare GPs' usage of different PPIs and explore how GPs' PPI prescribing changes 
      following the introduction of a cheaper competitor. METHODS: PPI prescribing data 
      (PACT) for 53 GPs, who were selected as regular users of a teaching hospital, 
      were monitored from January 1995 to December 1997. The GPs were located in two 
      adjoining health districts and had been interviewed about influences on their 
      decisions to begin prescribing lansoprazole. The PPI prescribing data were 
      collected for the teaching hospital and the general hospital in the adjoining 
      district. RESULTS: Complete prescribing data were available for 50 GPS: Total PPI 
      prescribing increased throughout the study due mainly to increasing use of the 
      new PPIS: Use of the new PPIs increased from 6 to 24% over 3 years. The 
      proportion of maintenance doses prescribed increased from 3 to 12%. There was a 
      23-fold difference in total PPI prescribing and an 87-fold difference in 
      lansoprazole prescribing between the highest and lowest prescribers. The uptake 
      of pantoprazole was slower than that of lansoprazole. A rapid increase in the use 
      of lansoprazole by the GPs followed an increase in use in the teaching hospital. 
      CONCLUSION: Hospital prescribing was an important influence on the choice of PPI 
      used by GPS: The wide variation in PPI prescribing suggests that there is scope 
      for improvement in the quality and cost of PPI prescribing.
FAU - Jones, M I
AU  - Jones MI
AD  - Department of Primary Care and General Practice, University of Birmingham, 
      Edgbaston, Birmingham B15 2TT, UK.
FAU - Greenfield, S M
AU  - Greenfield SM
FAU - Jowett, S
AU  - Jowett S
FAU - Bradley, C P
AU  - Bradley CP
FAU - Seal, R
AU  - Seal R
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Fam Pract
JT  - Family practice
JID - 8500875
RN  - 0 (2-Pyridinylmethylsulfinylbenzimidazoles)
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Benzimidazoles)
RN  - 0 (Proton Pump Inhibitors)
RN  - 0 (Sulfoxides)
RN  - 0K5C5T2QPG (Lansoprazole)
RN  - D8TST4O562 (Pantoprazole)
RN  - KG60484QX9 (Omeprazole)
SB  - IM
MH  - 2-Pyridinylmethylsulfinylbenzimidazoles
MH  - Anti-Ulcer Agents/economics/*therapeutic use
MH  - Benzimidazoles/economics/*therapeutic use
MH  - Drug Costs/statistics & numerical data
MH  - Drug Prescriptions/economics/*statistics & numerical data
MH  - Drug Utilization/*statistics & numerical data/trends
MH  - England
MH  - Family Practice/education/*statistics & numerical data
MH  - Female
MH  - Health Services Research
MH  - Hospitals, Teaching
MH  - Humans
MH  - Lansoprazole
MH  - Male
MH  - Omeprazole/analogs & derivatives/economics/*therapeutic use
MH  - Pantoprazole
MH  - Practice Patterns, Physicians'/*statistics & numerical data/trends
MH  - *Proton Pump Inhibitors
MH  - Sulfoxides/economics/*therapeutic use
EDAT- 2001/05/18 10:00
MHDA- 2001/07/28 10:01
CRDT- 2001/05/18 10:00
PHST- 2001/05/18 10:00 [pubmed]
PHST- 2001/07/28 10:01 [medline]
PHST- 2001/05/18 10:00 [entrez]
AID - 10.1093/fampra/18.3.333 [doi]
PST - ppublish
SO  - Fam Pract. 2001 Jun;18(3):333-8. doi: 10.1093/fampra/18.3.333.